A Study With Pentasa in Patients With Active Crohn's Disease
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Crohn´s Disease
In brief
The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.
Key facts
- Study ID
- NCT00862121
- Run by
- Ferring Pharmaceuticals
- People needed
- 20
- Starts
- 2009-04-01
- Expected to finish
- 2010-10-01
- Last updated by the study team
- 2012-03-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- San Diego Clinical Trials — San Diego, California, United States
- Clinical Research of West Florida — Clearwater, Florida, United States
- Atlanta Gastroenterology Specialists — John's Creek, Georgia, United States
- Center for Digestive and Liver Disease, Inc — Mexico, Montana, United States
- Wake Research Associates — Raleigh, North Carolina, United States
- Consultants for Clinical Research Inc. — Cincinnati, Ohio, United States
- Hartwell Research Group, LLC — Anderson, South Carolina, United States
- CHC Saint Joseph — Liège, Belgium
- Herlev University Hospital — Copenhagen, Denmark
- Investigational Site — Lille, France
- Investigational Site — Berlin, Germany
- Internist Gastroenterologie, Evangelisches Krankenhaus Kalk Akad. Lehrkrankenhaus für die Universität Köln — Cologne, Germany
- Gemeinschaftspraxis — Leipzig, Germany
- Lunds Lasaret — Lund, Sweden
- Addenbrookes Hospital — Cambridge, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.